Clinical trial
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
NCT00446836 · The Methodist Hospital Research Institute, Other · Completed
Key facts
| NCT number | NCT00446836 |
|---|---|
| Title | Efficacy and Safety Study of Xyotax to Treat Prostate Cancer |
| Official title | Phase II Study of Xyotax in Advanced Hormone Refractory Prostate Cancer |
| Lead sponsor | The Methodist Hospital Research Institute, Other |
| Collaborators | Cellular Therapeutics |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Paclitaxel polyglumex (Xyotax) |
| Enrollment | 29 |
| Start date | Mar 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Mar 13, 2007 |
| Last update posted | Mar 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: